Details

Autor(en) / Beteiligte

• Martín, Miguel
• Seguí, Miguel A
• Antón, Antonio
• Ruiz, Amparo
• Ramos, Manuel
• Adrover, Encarna
• Aranda, Ignacio
• Rodríguez-Lescure, Alvaro
• Große, Regina
• Calvo, Lourdes
• Barnadas, Agustí
• Isla, Dolores
• Martinez del Prado, Purificación
• Ruiz Borrego, Manuel
• Zaluski, Jerzy
• Arcusa, Angels
• Muñoz, Montserrat
• López Vega, José M
• Mel, José R
• Munarriz, Blanca
• Llorca, Cristina
• Jara, Carlos
• Alba, Emilio
• Florián, Jesús
• Li, Junfang
• López García-Asenjo, José A
• Sáez, Amparo
• Rios, María José
• Almenar, Sergio
• Peiró, Gloria
• Lluch, Ana

Titel

Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer

Ist Teil von

• The New England journal of medicine, 2010-12, Vol.363 (23), p.2200-2210

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2010

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• As compared with the standard regimen, the combination of docetaxel, doxorubicin, and cyclophosphamide reduced the risk of recurrence of node-negative early-stage breast cancer, but it offered no survival advantage and was associated with significantly higher rates of toxicity. The survival benefits of adjuvant chemotherapy for patients with early-stage breast cancer are well established. The 15-year survival results from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 1 showed that a combined chemotherapy regimen of cyclophosphamide, methotrexate, and fluorouracil (CMF) reduces annual recurrence and death rates, a benefit that is largely independent of tamoxifen use or nonuse, estrogen-receptor status, nodal status, and other tumor characteristics. 1 This meta-analysis also showed that anthracycline-based regimens offer an additional advantage over CMF. More recent studies and several other meta-analyses of randomized trials have shown that adding a taxane to anthracycline-based adjuvant therapy reduces the . . .